Search academic texts

Information × Registration Number 0219U003160, 0117U000277 , R & D reports Title To establish the factors, influencing survival in case of long-term therapy with tyrosine kinase inhibitors and to develop principles of efficient administration of these agents in patients with chronic myeloid leukemia popup.stage_title Head Maslyak Zvenyslava, Registration Date 24-01-2019 Organization LVIV RESEARCH INSTITUTE OF BLOOD PATHOLOGY AND TRANSFUSIONAL MEDICINE popup.description2 Treatment, monitoring and analysis of clinical and laboratory parameters of 74 patients within 5 groups depending on the type and peroid of treatment were continued. The influence of different clinical and laboratory factors on 10-year and 3-year overall survival in the group of CML patients was evaluated. Response to treatment with generic imatinib and nilotinib as the first line therapy was evaluated in the group of CML patients. A separate group of patients with resistant mutations of the fusion gene was distinguished and efficacy of their treatment was analyzed. Investigation of residual leukemic stem cells was initiated using immunophenotyping of peripheral blood mononuclear cells. The course and outcome of pregnancy was analyzed the in group of women with CML, as well as in partners of men with CML (24 cases). Product Description popup.authors Бойко Ольга Ігорівна Везденко Л. О. Вороняк М.І. Кокоруз М. В. Котлярчук Констянтин Богданович Масляк Звенислава Володимирівна Сімонова Мар'яна Іванівна Сусіда Х. Р. Томашевська Н.Я. Худзій С. С. Цяпка Орест Миколайович Юрчишак І. М. popup.nrat_date 2020-04-02 Close